Eurofins Viracor BioPharma Services has officially moved into its new, purpose-built 96,000 ft2 facility in Lenexa, Kansas, US. This strategic expansion marks a major milestone in our continued growth and commitment to delivering advanced analytical and clinical trial solutions to the biopharmaceutical industry.
Previously co-located with Eurofins Viracor, the new facility allows each organisation to focus on its core mission — Viracor on Clinical Diagnostics and Eurofins Viracor BioPharma Services on BioPharma Services. The Kansas City region continues to offer strategic advantages, including access to top-tier scientific talent and a thriving life sciences ecosystem.
The new site expands capabilities in sequencing, precision medicine, cell-based assays, high-complexity flow cytometry, vaccine development, and biomarker analysis. It supports critical endpoints such as immunogenicity, neutralising antibodies, target engagement, and mechanism-of-action studies.
Designed for scalability and efficiency, the facility features advanced analytical platforms, integrated automation, and expanded biorepository capacity. It enhances support for custom assay development, GLP/GCLP-compliant validation, and clinical sample testing across all phases of drug development.
As part of the Eurofins Clinical Trial Solutions network, Eurofins Viracor BioPharma Services is uniquely positioned to deliver integrated services across bioanalysis, central laboratory, pathology, specialty testing, and clinical trial supplies — accelerating the development of life-enhancing therapies.